ECE2017 Eposter Presentations: Diabetes, Obesity and Metabolism Cardiovascular Endocrinology and Lipid Metabolism (29 abstracts)
Identifiying underdiagnosed or undertreated patients with familial hypercholesterolemia from the central laboratory registries
Cem Haymana 1 , Hamza Berlik 2 , Yalcin Gunes 2 , Orhan Enes Tuncez 2 , Cihat Aytekin 2 , Zafer Tapikara 2 , Huseyin Guzel 2 , Ozlem Ozturk 3 , Cem Barcin 4 , Taner Ozgurtas 3 , Omer Azal 1 & Alper Sonmez 1
1Department of Endocrinology and Metabolism, Gulhane Training and Research Hospital, Ankara, Turkey; 2Gulhane School of Medicine, Health Sciences University, Ankara, Turkey; 3Department of Biochemistry, Gulhane Training and Research Hospital, Ankara, Turkey; 4Department of Cardiology, Gulhane Training and Research Hospital, Ankara, Turkey.
Objective: Familial hypercholesterolemia (FH) is a life-threatening genetic disease associated with elevated low density lipoprotein cholesterol (LDL-C) and premature coronary heart disease that is globally underdiagnosed and undertreated. This study aimed to search for the demographical characteristics, awareness and treatment adherence of underdiagnosed or undertreated FH patients from the records of the central biochemistry laboratory.
Methods: Patients with a central laboratory measurement of LDL-C >250 mg/dl were identified. Patients with older than 18 years without secondary causes of dyslipidemia were called by medical students and interviewed about demographic characteristics, awareness of dyslipidemia and treatment adherence.
Results: A total of 147 patients (mean age 51.7±16.6 years, 59.2% female) were interviewed. The mean LDL-C levels were 292.8±49.9 mg/dl. According to the Dutch Lipid Clinic Network Criteria, the patients with definite, probable and possible FH were 18.4%, 66.0% and 15.6%, respectively. Although the majority of the patients (93.9%) were aware of their high LDL-C levels, only about half of them (n=75, 51.0%) were under treatment. Of all the patients who were interviewed, 21% (n=31) had never taken, and 28% (n=41) had stopped taking lipid-lowering drug.
Conclusion: The results of this pilot study show that, undiagnosed or undertreated FH patients can practically be detected from the high LDL-C registries of the Hospital Laboratories. Nationwide implementation of this method may help us reach and manage these high-risk patients.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more